Company intelligence / Profile preview
Zeria Pharmaceutical Co., Ltd.
Chuo-ku, Tokyo, Japanzeria.co.jp ↗
- Ownership
- Private
- Employees
- ~1839
- Development stage
- Commercial
01
Overview
Zeria has multiple approved drugs including Acotiamide for functional dyspepsia, Fidaxomicin for Clostridium difficile infections, and recently received approval for Patiromer Sorbitex Calcium (Veltassa) for hyperkalemia in Japan. The company has several products in various stages of clinical development.
- Therapeutic areas
- GastroenterologyCardiovascularUrologyNephrologyOphthalmologyInfectious Diseases
- Modalities
- Small molecule drugsBiological productsChemical drugsPolymerAntibody
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
CSL ViforAgastra-Lab s.r.lFaes FarmaMeiji Seika PharmaUnited Italian Trading Corporation Pte. Ltd.Pioneer
Beyond the preview
Go deeper on Zeria Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zeria Pharmaceutical Co., Ltd..